Raltegravir ( DrugBank: Raltegravir )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2
26	HTLV-1関連脊髄症	4
93	原発性胆汁性胆管炎	1
265	脂肪萎縮症	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01767701 (ClinicalTrials.gov)	April 2013	7/1/2013	Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis	A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI	Relapsing Remitting Multiple Sclerosis	Drug: Raltegravir	Queen Mary University of London	Merck Sharp & Dohme Corp.	Completed	18 Years	55 Years	All	23	Phase 2	United Kingdom
2	EUCTR2012-004847-61-GB (EUCTR)	16/01/2013	18/12/2012	INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS	A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS)	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: ISENTRESS Product Name: raltegravir INN or Proposed INN: lactose monohydrate	Queen Mary University of London	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom

26. HTLV-1関連脊髄症

臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02655471 (ClinicalTrials.gov)	July 1, 2017	16/11/2015	Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection	Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study	HTLV-I Infections;Tropical Spastic Paraparesis	Drug: Raltegravir and Zidovudine	Universidad Peruana Cayetano Heredia	Merck Sharp & Dohme Corp.	Completed	18 Years	N/A	All	10	Early Phase 1	Peru
2	NCT01867320 (ClinicalTrials.gov)	September 5, 2013	21/5/2013	Raltegravir for HAM/TSP	Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)	HTLV-I Infection	Drug: Raltegravir	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	19	Early Phase 1	United States
3	NCT01620736 (ClinicalTrials.gov)	January 2012	25/1/2012	Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Human T-cell Leukemia Virus Type 1 Infection	Drug: Raltegravir	Washington University School of Medicine	Merck Sharp & Dohme Corp.	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
4	NCT01000285 (ClinicalTrials.gov)	September 2010	19/10/2009	EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma	Leukemia-Lymphoma, Adult T-Cell	Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir	Washington University School of Medicine	NULL	Completed	18 Years	N/A	All	18	Phase 1/Phase 2	United States

93. 原発性胆汁性胆管炎

臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03954327 (ClinicalTrials.gov)	June 29, 2020	7/5/2019	Combination Antiretroviral Therapy (cART) for PBC	Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)	Primary Biliary Cholangitis	Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF);Drug: Raltegravir;Drug: Placebo Oral Capsule [CEBOCAP]	University of Alberta	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	60	Phase 2	Canada

265. 脂肪萎縮症

臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01164605 (ClinicalTrials.gov)	October 2010	14/7/2010	Pilot Study of Raltegravir Lipodystrophy IISP	Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment	HIV Infection	Drug: Raltegravir	Southern California Institute for Research and Education	Merck Sharp & Dohme Corp.	Recruiting	N/A	N/A	Both	30	N/A	United States
2	NCT00656175 (ClinicalTrials.gov)	September 2008	2/4/2008	Raltegravir Therapy for Women With HIV and Fat Accumulation	Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation	HIV Infections;Lipodystrophy	Drug: raltegravir	University of California, Los Angeles	Merck Sharp & Dohme Corp.;Case Western Reserve University;Vanderbilt University;Tufts University;University Health Network, Toronto	Completed	18 Years	N/A	Female	39	Phase 2	United States;Canada

先頭へ